15 September 2020

Practical User Guide for Electronic Application Forms (eAF) for human and veterinary medicinal products in the EU

Version 1.8.
Note to readers

This guidance reflects the current state of knowledge and is subject to future updates to take new information on-board. Therefore, it is important that comments are fed back to the eAF User Group by e-mail EMA IT service desk (https://servicedesk.ema.europa.eu).

Screenshots in this document have been, in most cases taken using eAF version 1.24. In some cases, this guidance will still use screenshots based on earlier versions. It is not possible to match this guidance document with one exact version of the eAF. However, information about new functionalities or changes are in the up to date release notes at: http://esubmission.ema.europa.eu/eaf/index.html.
### Document History

#### Change Record

<table>
<thead>
<tr>
<th>Version</th>
<th>Author(s)</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.0</td>
<td>eAF User Group</td>
<td>This document has been prepared by the sub-group on guidance and information of the eAF User Group in collaboration with CMDh and CMDv</td>
</tr>
<tr>
<td></td>
<td>eAF User Group</td>
<td>First draft for revision, made the document in line with reported corrections, improved consistency with the Q&amp;A on eAF and aligned with changes of the eAFs version 1.18</td>
</tr>
<tr>
<td>1.1</td>
<td>eAF User Group</td>
<td>Indicating acceptance of an image of a text snippet for EMA, additional advice for optimising the PDF file for eCTD purpose, minor editorial changes after review</td>
</tr>
<tr>
<td>1.2</td>
<td>eAF Sub-Group on Guidance</td>
<td>Update of the guidance to include new features of version 1.20 as well as to improve several sections based on user comments.</td>
</tr>
<tr>
<td>1.3</td>
<td>eAF Sub-Group on Guidance</td>
<td>Consolidation of review comments.</td>
</tr>
<tr>
<td>1.4.1</td>
<td>eAF Sub-Group on Guidance</td>
<td>Deleting the note in section 2.5.3 pointing to a workaround not meaningful.</td>
</tr>
<tr>
<td>1.4.2</td>
<td>eAF Sub-Group on Guidance</td>
<td>Update based on eAF v1.20.0.3 (Screenshots updated as necessary, advice on button “Add All” for member states in MAA hum/vet and REN), correction of link to EMA IT service desk</td>
</tr>
<tr>
<td>1.4.3</td>
<td>eAF Sub-Group on Guidance</td>
<td>Clean version for publication</td>
</tr>
<tr>
<td>1.6</td>
<td>EMA</td>
<td>Updated to reflect eAF v1.22.0.0</td>
</tr>
<tr>
<td>1.7</td>
<td>EMA / eAF Sub-Group on Guidance</td>
<td>Updated to reflect eAF v1.23.0.0 and the NtA changes triggering the updated version of the eAF.</td>
</tr>
<tr>
<td>1.7.1</td>
<td>eAF Sub-Group on Guidance</td>
<td>Including clarification on section 2.5.4</td>
</tr>
<tr>
<td>1.8</td>
<td>EMA</td>
<td>Updated to reflect eAF v1.24.0.0 (mainly variation form)</td>
</tr>
</tbody>
</table>

#### Reviewers

<table>
<thead>
<tr>
<th>Version</th>
<th>Name</th>
<th>Organisation</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Version, Name, Organisation

<table>
<thead>
<tr>
<th>Version</th>
<th>Name</th>
<th>Organisation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.0</td>
<td>Representatives of NCA and EMA</td>
<td>eAF Full Group,</td>
</tr>
<tr>
<td></td>
<td>Representatives of NCA and EMA</td>
<td>CMDh,</td>
</tr>
<tr>
<td>1.1</td>
<td>Representatives of NCA and EMA</td>
<td>CMDv</td>
</tr>
<tr>
<td>1.2</td>
<td>Representatives of NCA and EMA</td>
<td>eAF Full Group, CMDh and CMDv, eSub CMB</td>
</tr>
<tr>
<td>1.7</td>
<td>Representatives of NCA and EMA</td>
<td>eAF Full Group, CMDh and CMDv, eSub CMB</td>
</tr>
</tbody>
</table>

### Distribution

<table>
<thead>
<tr>
<th>Version</th>
<th>Distributed to</th>
<th>Method of distribution</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.0</td>
<td>General public</td>
<td>Published on the EMA eSubmission website</td>
</tr>
<tr>
<td>1.1</td>
<td>General public</td>
<td>Published on the EMA eSubmission website</td>
</tr>
<tr>
<td>1.4</td>
<td>General public</td>
<td>Published on the EMA eSubmission website</td>
</tr>
<tr>
<td>1.5</td>
<td>General public</td>
<td>Published on the EMA eSubmission website</td>
</tr>
<tr>
<td>1.6</td>
<td>General public</td>
<td>Published on the EMA eSubmission website</td>
</tr>
<tr>
<td>1.7</td>
<td>General public</td>
<td>Published on the EMA eSubmission website</td>
</tr>
<tr>
<td>1.7.1</td>
<td>General public</td>
<td>Published on the EMA eSubmission website</td>
</tr>
<tr>
<td>1.7.2</td>
<td>General public</td>
<td>Published on the EMA eSubmission website</td>
</tr>
<tr>
<td>1.8</td>
<td>General public</td>
<td>Published on the EMA eSubmission website</td>
</tr>
</tbody>
</table>

### Entering operation

<table>
<thead>
<tr>
<th>Version</th>
<th>Date</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.0</td>
<td>July 2015</td>
<td>This guidance document should always be read in conjunction with the respective regulatory guidance documents on human and veterinary medicinal products. In parallel a Q&amp;A document is available providing quick up-to-date additional information regarding usage of eAFs.</td>
</tr>
<tr>
<td>1.1</td>
<td>October 2015</td>
<td>This is an interim update. A next update will follow once the eAF version 1.19 is published.</td>
</tr>
<tr>
<td>1.4</td>
<td>June 2016</td>
<td>This is an interim update. Further updates are expected based on user feedback once version 1.20 is published.</td>
</tr>
<tr>
<td>1.5</td>
<td>October 2016</td>
<td>Updated version based on eAF v1.20.0.3</td>
</tr>
<tr>
<td>1.6</td>
<td>December 2017</td>
<td>Updated version based on eAF v1.22.0.0</td>
</tr>
<tr>
<td>1.7</td>
<td>July 2018</td>
<td>Updated version based on eAF v1.23.0.0</td>
</tr>
<tr>
<td>Version</td>
<td>Date</td>
<td>Comments</td>
</tr>
<tr>
<td>---------</td>
<td>-----------------</td>
<td>--------------------------------------</td>
</tr>
<tr>
<td>1.7.1.</td>
<td>August 2018</td>
<td>Updated version based on version 1.7</td>
</tr>
<tr>
<td>1.7.2.</td>
<td>September 2018</td>
<td>Updates based on minor comments</td>
</tr>
<tr>
<td>1.8</td>
<td>September 2020</td>
<td>Updates based on eAF v1.24.0.0</td>
</tr>
</tbody>
</table>
Contents

Note to readers ...........................................................................................................2
Document History ......................................................................................................3
  Change Record ........................................................................................................3
  Reviewers ................................................................................................................3
  Distribution .............................................................................................................4
  Entering operation .................................................................................................4
Contents .....................................................................................................................6
Purpose and general technical rules .................................................................10
  Purpose of this document ..................................................................................10
  Referential term change request processes .....................................................10
  Access to the forms and news on updates .....................................................11
  Adobe Reader requirements and IT security settings ..................................11
  Opening the form ..............................................................................................12
  Navigating the forms .........................................................................................12
  Integration of the forms into dossier ..............................................................13
  Export of XML data ..........................................................................................14
  Import of the XML data ....................................................................................14
  Update of the XML data ....................................................................................15
  Data fields and formats .......................................................................................15
  Providing OMS organisation details to auto-populate address fields ...........17
  File Naming Convention ..................................................................................20
  Signature ............................................................................................................21
  Saving the form .................................................................................................22
MAA FORM (human) ..........................................................................................22
Administrative Data ...............................................................................................23
  Declaration and Signature .............................................................................23
  Product (Invented) name .................................................................................23
  Pharmaceutical form .........................................................................................23
  Strength(s) ........................................................................................................24
  Active Substance(s) .........................................................................................26
  Base/Active moiety .............................................................................................27
  Applicant ............................................................................................................27
  Person confirming fees will be/ have been paid, on behalf of the Applicant ....29
1. Type of application .............................................................................................29
  1.1. This application concerns ........................................................................30
    1.1.1. A Centralised Procedure ....................................................................31
    1.1.2. A Mutual Recognition Procedure ....................................................31
    1.1.3. A Decentralised Procedure ................................................................32
    1.1.4. A National Procedure .......................................................................32
  1.2. Orphan Medicinal Product Information (human only) ..........................32
1.3. Application for a change to existing marketing authorisation leading to an extension as referred to in Annex I of Regulation (EC) no 1234/2008, or any national legislation, where applicable? .................................................................................................................. 33

1.4. This application is submitted in accordance with the following article in Directive 2001/83/EC as amended............................................................................................................................................. 33

1.5. Consideration of this application requested under the following article of Directive 2001/83/EC or Regulation (EC) No 726/2004 ............................................................................................................................................. 33

1.6. Requirements according to Regulation (EC) N° 1901/2006 (‘Paediatric Regulation’) ... 33

2. **Marketing Authorisation Application........................................................................34**

2.1. Names(s) and ATC code........................................................................................................... 34

2.1.1. Proposed (invented) name of the medicinal product in the European Union / Member State/Iceland/Lichtenstein/ Norway ........................................................................................................... 34

2.1.2. Active substance(s) ........................................................................................................... 34

2.1.3. Pharmacotherapeutic group ............................................................................................ 36

2.2. Strength, pharmaceutical form, route of administration, container and pack sizes .... 36

2.2.1. Strength and pharmaceutical form (use current list of standard terms – European Pharmacopoeia) ................................................................................................................................. 36

2.2.2. Route(s) of administration (current list standard terms - European Pharmacopoeia) 37

2.2.3. Container, closure and administration device(s) ............................................................... 38

2.2.4. Medical Devices ............................................................................................................... 39

2.3. Legal status ......................................................................................................................... 39

2.4. Marketing authorisation holder / contact persons / company ........................................... 40

2.4.1. Proposed responsible marketing authorisation holder/person ...................................... 40

2.4.2. Person/company authorised for communication on behalf of the applicant during the procedure ................................................................................................................................. 42

2.4.3. Person/company authorised for communication ............................................................... 43

2.4.4. Summary of the applicant pharmacovigilance system ...................................................... 43

2.5. Manufacturers .................................................................................................................... 43

2.5.1. Authorised manufacturer(s) (or importer(s)) responsible for batch release in the EEA43

2.5.2. Manufacturer(s) of the medicinal product and site(s) of manufacture ......................... 45

2.5.3. Manufacturer(s) of the active substance(s) and site(s) of manufacture .................... 48

2.5.4. Contract companies used for clinical trial(s) (including bioavailability and bioequivalence studies) included in the application or used for the validation of blood product manufacturing processes .................................................................................................... 50

2.6. Quantitative and Qualitative Composition ....................................................................... 51

2.6.1. Qualitative and Quantitative composition in terms of the active substance(s) and the excipient(s) ................................................................................................................................. 51

2.6.2. List of materials of animal and/or human origin contained/ used in the manufacturing process of the medicinal product? ..................................................................................... 54

2.6.3. Is an EMEA certificate for a Plasma Master File (PMF) issued or submitted in accordance with Directive 2001/83/EC Annex I, Part III, being used for this MAA? .................. 54

2.6.4. Does the medicinal product contain or consist of Genetically Modified Organisms (GMOs) within the meaning of Directive 2001/18/EC? ................................................................. 54

3. **Scientific advice .................................................................................................................54**

3.1. Was there formal scientific advice(s) given by EMA for this medicinal product? ........ 54

3.2. Was there scientific advice(s) given by Member State(s) for this medicinal product? ... 54
4. Other marketing authorisation applications ........................................ 54
5. Annexed documents (where appropriate) ........................................ 54

MAA FORM (veterinary) ..................................................................... 55
Administrative data ........................................................................ 55
Declaration and signature ................................................................. 55

1. Type of application ......................................................................... 56
1.1. This application concerns ............................................................. 56
1.1.1. A Centralised Procedure ......................................................... 56
1.1.2. A Mutual Recognition Procedure ......................................... 56
1.1.3. A Decentralised Procedure .................................................... 56
1.1.4. A National Procedure ............................................................. 57
1.2. Is this an application for a change to your existing marketing authorisation leading to an extension as referred to in Annex I of Regulation (EC) No 1234/2008, or any national legislation, where applicable? ........................ 57
1.3. This application is submitted in accordance with the following articles in Directive 2001/82/EC ........................................................................ 57
1.4. MRL status (only for food-producing species) .............................. 57
1.5. Consideration of this application is also requested under the following article in Directive 2001/82/EC or Regulation (EC) No 726/2004 ................................................................. 59

2. Marketing authorisation application particulars ............................. 59
2.1. Name(s) and ATC vet code and target species ............................ 59
2.1.1. Proposed (invented) name of the veterinary medicinal product in the European Union / Member State/Iceland/Lichtenstein/ Norway .................................................. 59
2.1.2. Active substance(s) ................................................................. 59
2.1.3. Pharmacotherapeutic group (Please use current ATC vet code) ...................................................................................... 60
2.1.4. Target species ...................................................................... 60
2.2. Strength, pharmaceutical form, route of administration, container and pack sizes .... 60
2.2.1. Strength and pharmaceutical form (use current list of standard terms – European Pharmacopoeia) ................................................. 60
2.2.2. Route(s) of administration (use current list of standard terms - European Pharmacopoeia) ............................................................. 60
2.2.3. Container, closure and administration device(s), including description of material from which it is constructed. (use current list of standard terms - European Pharmacopoeia) .... 61
2.3. Legal status .............................................................................. 62
2.4. Marketing authorisation holder / contact persons / company ...... 62
2.5. Manufacturers ........................................................................ 62
2.6. Quantitative and qualitative composition ...................................... 62
2.6.1. Qualitative and Quantitative composition in terms of the active substance(s) and the excipient(s) ......................................................... 62
2.6.2. List of materials of animal and/or human origin contained or used in the manufacturing process of the medicinal product? ............................................................. 62
2.6.3. Does the veterinary medicinal product contain or consist of Genetically Modified Organisms (GMOs) within the meaning of Directive 2001/18/EC? ........................................... 62

3. Scientific advice ............................................................................. 62
3.1. Was there formal scientific advice(s) given by CVMP for this veterinary medicinal product? ................................................................. 62
3.2. Was a scientific recommendation(s) given by Member State(s) for this veterinary medicinal product? ......................................................... 62
4. Other marketing authorisation applications ..............................................................62
5. Annexed documents (where appropriate) .................................................................62

VARIATION FORM .............................................................................................................63
1. Application for variation to a marketing authorisation .................................63
2. Products concerned by this application .................................................................65
3. Types(s) of changes(s) ...........................................................................................66

Present and proposed section – text fields .................................................................69
Present and proposed section – address details .........................................................70

4.a Type IB and Type II variations – new indications – orphan medicinal product information .....................................................................................................71

4.b Type IB and Type II variations – Paediatric Requirements ............................72
4.c Type II variations – Extended data exclusivity/market protection ..........73

Annexed documents (where appropriate) .................................................................74
Declaration of the applicant ........................................................................................74
Signature ........................................................................................................................74

RENEWAL FROM ..........................................................................................................75
1. Application form for renewal of a marketing authorisation ........................75
2. Approved manufacturers .........................................................................................77
3. Quantitative and qualitative composition in terms of the active substance(s) and the excipient(s) ........................................................................................................80

4. Documents appended to this application .............................................................81
Declaration and Signature ............................................................................................82
Purpose and general technical rules

The following pages provide general technical information regarding all four PDF format electronic application forms. Additional information related to the specific application forms is provided in separate sections.

Purpose of this document

As part of a submission package, it is mandatory for all (Human and Veterinary) submissions in EU Member States to use the electronic application form. The paper MS Word application forms are no longer provided by Notice to Applicants (NtA).

This document provides practical and technical support on the use of the Electronic Application Forms (eAFs) for human and veterinary medicinal products, and in addition to the regulatory user guide for the electronic application form for a marketing authorisation which is available for human medicinal products at CMDh and for veterinary medicinal products at CMDv. This document should be read in the context with the regulatory guidance referenced above.

Note: Reliable regulatory information must be taken from the (regulatory) user guides of the application form only.


Field level help or tool tips are also available in the eAF by moving the mouse pointer over each field of the electronic forms.

Note: If the tooltips are not visible when you hover over the fields in the forms please contact your IT support.

The release notes list any new functionality when new versions of the forms become available. It is strongly recommended to review the release notes each time a new version of the forms is available.

Information is also available relating to the use of the forms in the release notes, for example some workaround solutions.

If you encounter an issue with a specific field, please refer to the Known Issues ‘section in the release notes for the specific form here on the eSubmission website. Raise any new issues with the EMA Service Desk.

If the information cannot be included in the form, please review any workaround solutions provided in the release notes, or use an annex. In case of any further technical queries, please contact the EMA Service Desk.

Referential term change request processes

In case of a missing term and as a general rule, in order to complete an eAF, use the RMS Change Request processes as outlined in the Referential Management Services (RMS) operating model document. Please submit a request using the SPOR Portal: http://spor.ema.europa.eu/rmswi/#/

Provide as much supporting documentation as possible (e.g. name of the product concerned, SmPC, etc.). Please note you need to be registered with SPOR prior to submission of change requests: https://register.ema.europa.eu/identityiq/login.jsf. The user guide for managing referential and organisation data in eAF is available here.
If you need to request a missing substance in order to complete an eAF, please submit a request for substance insertion with the corresponding SmPC to the EMA Service Desk portal - https://servicedesk.ema.europa.eu/.

**Access to the forms and news on updates**

The use of the electronic application form has become mandatory as of July 1st, 2015, for the centralised procedure and as of January 1st, 2016, for all MRP/DCP and national procedures. Technical details are accessible at http://esubmission.ema.europa.eu/eaf/index.html. The latest versions of the respective forms can also be found there.

Updates to the electronic application forms are expected to reflect any changes agreed by the European Commission, in consultation with the competent authorities of the Member States and the European Medicines Agency (EMA).

**Note:** Regular updates occur according to release planning.

The simplest way to keep up to date with changes to eAF is to subscribe to the eAF RSS feed.

For more information about RSS feeds, see The EMA’s Guide to RSS.

**Adobe Reader requirements and IT security settings**

When opening the eAF for the first time with Adobe Reader™, click the exclamation mark at the top of the left hand side menu bar and once a yellow bar opens across the top of the form, then click **Trust this document one time only** or **Trust this document always**. It has been noted that for some users the Trust this document one time only option works better.

Adobe™ no longer supports version 9 or earlier, so we strongly advise to upgrade Adobe Reader™ to the latest version. Please keep updated about Adobe™ supported versions.

The minimum specification to use eAF is Adobe Reader™ version 10 or above. If you wish to continue using Adobe Acrobat 9 and eAFs are working fine with it then do so, however should there be any compatibility issues then Adobe is unable to support the EMA.
Extensive testing has not been performed using Linux or Mac OS environments, however there are no known issues preventing the use as long as Adobe reader, and an internet connection are accessible.

**Note**: The built-in PDF viewer with Mozilla Firefox and Google Chrome do not support XFA based PDF forms. Guidance to assist with resolving this issue can be found [here](http://helpx.adobe.com/livecycle/kb/xfa-forms-firefox-chrome.html).

If you receive this error message when opening the form the first time **click Options** and **click Trust this document** always.

**Note**: If the IT policy of your local organisation prohibits you from making changes to a security setting, contact your local IT service desk and request that they allow access to the following URL: [http://eaf.ema.europa.eu/eaf/services/EutctService?wsdl](http://eaf.ema.europa.eu/eaf/services/EutctService?wsdl)

**Important**: The web services location, managed by the EMA, enables many of the forms’ fields, searches and drop-down lists to be populated dynamically. Without access, the form **cannot** be completed. Please note that ‘Trusting’ the forms is an essential step to access the drop-down lists. Some issues have been reported when multiple PDF documents are open at the same time and some of the documents have been signed with Adobe Sign. This can prevent the eAFs from working and if you experience this issue, please close the document containing the Adobe Sign signature. Please note that the eAFs must not be signed using Adobe Sign or any other digital signature tool.

**Opening the form**

The eAF forms are connected to a web services and this means they can take longer to open than conventional documents. When a form is opened, lists are loaded from EUTCT and RMS and some have complex built in ‘business validation rules’ which can make the forms heavy.

Drop-down lists are also loaded into the form and when initially opened and this is one of the reasons that the form takes longer time to open.

The average response times for how long it takes to open a current version of the eAF depends on the form. The responses are also different for new forms that are being opened directly from the eAF website as opposed to those that have been filled in, locked and submitted by the MAA/MAH.

**Note**: The searchable fields will not work if there is no internet connection (such as Active substance, Excipients and ATC code).

**Navigating the forms**

You can jump between different sections of the forms by clicking your mouse on the bold blue section name. When you click to this text you are automatically taken to the Table of Contents section from where you can navigate to any other part of the form.
This functionality is limited in the locked forms where the table and contents and all the headers have been greyed out. The return to the Table of Contents will only work if the header is surrounded by dotted line.

It is also possible to jump back to the respective sections of the form footnote references in the end of the document and back to the relevant section in the form by clicking the section that is surrounded by a dotted line. This functionality is disabled in locked forms.

Integration of the forms into dossier

Only the final signed PDF created using the electronic forms should be submitted in the relevant part of the dossier. The XML data can be extracted from the pdf file. This action will be performed by agencies when receiving the pdf form. Therefore, applicants should refrain from providing the XML data file separately.

It is underlined that the forms are secured in such manner that no change can be brought outside filling the field, i.e. no bookmarks or hyperlinks can be added, no merging with other files can be done, no
comments can be brought in the pdf file. In addition, it is not allowed to add any attachments/hyperlinks to the document.

If the eAF.xml is stored in the eCTD sequence or VNeeS submission, an error during technical validation will be reported. It is of course strongly advised against printing out the form and scanning it in.

**Important:** You must not use the attachment function within the forms to attach supporting documents. Whilst this feature is visible in the Reader/Acrobat window under a paper clip ( ), it should not be used. Unfortunately this functionality cannot be removed as it is inherent to adobe forms.

**Important:** Do not use the bookmarking functionality in PDF as this affects on how the forms are locked and may lead to rejection by receiving agencies.

**Export of XML data**

The ‘**Export XML**’ function allows users to extract the content of the electronic form in the XML (eXtensible Mark-up Language) file format. This is useful in a number of ways, including:

1. The XML output can be used in other IT systems (for example receiving regulators can use this data to populate their systems).
2. Previously exported XML outputs may be imported into a new version of the form, as long as the underlying .xsd (XML Schema Definition) has not changed in the interim.
3. The XML file is much smaller than the PDF file so may be considered more suitable for archiving.

To extract and view the XML do the following:

1. Navigate to the Form Validation page in the PDF, and then click **Export XML** to create an XML file.
2. To export the full form xml (including the drop-down list cache in the envelope node of the schema), click **No** when asked 'Would you like to export just the user entered form data?'
3. To extract the user entered data only, click 'Yes' when asked 'Would you like to export just the user entered form data?'.
4. Save the file in your local file system and use your chosen XML file editor to view the data and its structure.

**Note:** You may also use the inbuilt export xml tool in Reader or Acrobat. The procedure to reach the inbuilt function varies in the different major software versions. The common procedure path for Reader 10 is: Extended>Export Data. The export can also be automated although the EMA does not provide a specific tool.

**Import of the XML data**

This function mainly used by industry in order to recover and reuse data from a previous eAF into a new one.

It is also possible to **import XML** data in the correct format, if you have previously exported XML data (as long as the underlying .xsd (XML Schema Definition) has not changed in the interim):

1. Navigate to the Form Validation page in the PDF, and click **Import XML** to open the file system browser to find a previously created XML file.
2. Once the xml is imported, save, close then re-open the form whilst online to refresh the lists.

Note: You may also use the built in import xml in Reader or Acrobat to import previously completed form data.

Important: Performing this procedure, may overwrite the cached drop-down lists with an older version. To ensure this is resolved, save, close and re-open the form whilst online. This will refresh the lists and overwrite any outdated list content in the form cache.

Note: It is possible that some information will be lost when you export and import data from an older version of eAF to a new version due to changes in the form, and underlying schema. However, if you export from unlocked version and import into new version you will be able to change content in the form.

When exporting from a 'locked version of the form' you can only make changes in the actual xml and import into the new version.

**Update of the XML data**

Concerns that the content will not remain the same after a couple of months (and require a print due to modified terms from controlled terms lists) are not justified as the terms will have a version ID which will assure that the display remains the same.

In case of updates of the eAF it will be possible to extract the data from the existing version of the form and import the data into the revised version. Most likely, manual correction may have to be done at least if data field types have been changed.

When any eAFs are opened when connected to the internet, an automatic version check is done to notify the user if a new version of the eAF is available for download. Drop down terms are always updated when opening the form. Click the Update lists button to update the list.

To manually check the version of eAF, do the following:

1. Right-click on the body of the form and select Document Properties or on the Acrobat menu bar click: File>Properties (PC keyboard shortcut= CTRL+D).
2. The Document Properties dialog window is displayed. Click the Custom tab to find version information.

Note: The NtA revision number of the form on the right hand side reflects the paper form on which the particular electronic form is based on. The version number of the eAF is displayed on the left hand side.

**Data fields and formats**

In the form square boxes indicate that multiple choices are possible while round boxes indicate that one choice excludes the other possibilities.
Free text fields have been implemented in a number of sections of the forms where no controlled terminology is available. Improvement is ongoing on finding best solution to implement structured data fields throughout the form. In some sections free text fields provide additional options to describe e.g. roles of a manufacturer where no controlled terminologies are available.

Normally, free text fields in the forms allow only plain text. Only in the table for present and proposed information text in the variation form inclusion of formatted text will be possible (see section 3 of VAR form). Tracked-changes functionality is currently not available in interactive Acrobat forms.

The user interface indicates where text fields, data fields or entire sections can be duplicated or eliminated by using "+" or "-" buttons.

<table>
<thead>
<tr>
<th>For each type of pack give:</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.2.3.1 Package size</td>
</tr>
<tr>
<td>[ ] +</td>
</tr>
</tbody>
</table>

eAFs are intelligent forms with built in business rules. Some sections are only displayed depending on previous selections. It is not necessary/possible to delete sections which are not required.

Once information is entered, the fields remain visible when un-ticking corresponding fields. To reduce the risk of accidental data loss completed sections when completed, are hidden. Data can only be deleted on a field by field basis by users. In some other cases, the values will be deleted when a different selection is chosen in the variations form when you switch between centralised and MR procedures.

The pop-up calendar fields allow you to select future months, and years within the form. With the calendar open, click the month/year and select the month/year option from the drop-down menu. Finally, click the day to close the calendar.

In some forms there are copy from xx/populate from xx and clone buttons to allow copying/duplicating information from previous sections to remove the need to re-enter data multiple times.

Please provide any proposals for implementation of certain sections/fields, any usability issues of the forms or certain character sets that you would like to see in any future implementation in order to meet your needs.

**Providing contact & address details**

Provide contact and address in a consistent way. Given there are a number of these sections required, the eAF provides users with the ability to reuse this data from one section to another. This reduces the need to repeat entry steps. See the example below:

**Copy contact details from Declaration Section**

**Copy contact details from 2.4.1 Section**

**Copy contact details from 2.4.2 Section**

There are two ways offered to complete the data fields: You can complete address data line by line manually or select these details from the Organisation Management Service (OMS) by using an appropriate identifier (see over-next sub-section). Use of OMS is strongly recommended and it should be noted that mandatory use of OMS in the eAFs is being discussed.
Manual completing address details

Information how the address details must be entered are provided in the tooltips when you hover over the corresponding field. The address details should only be entered manually exceptionally. The OMS data should always be used where possible.

<table>
<thead>
<tr>
<th>Company name</th>
<th>Pharma Company Ltd.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Address</td>
<td>Mainstreet 23</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>City/Locality/Town/Village</td>
<td>Capitaltown</td>
</tr>
<tr>
<td>State</td>
<td></td>
</tr>
<tr>
<td>County</td>
<td></td>
</tr>
<tr>
<td>Postcode</td>
<td>EF 2391 G</td>
</tr>
<tr>
<td>Country</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Telephone</td>
<td></td>
</tr>
<tr>
<td>E-mail</td>
<td></td>
</tr>
</tbody>
</table>

Providing OMS organisation details to auto-populate address fields

In order to facilitate entry of the large number of required organisation and address details; eAF is integrated with OMS data. This allows users to search and select organisations from OMS records resulting in the auto-completion of the related address fields. This is to simplify data entry and reduce the number of repetitive manual data entry steps. The eAF OMS integration is one of the first integrated systems under the Agency SPOR program.

In all eAFs where there are organisation and address details required (with the exception of CROs & Billing Addresses), users will see the following: after clicking Find Organisation:
This allows users to search for OMS organisations by using either:

- A unique Organisation ID\Location ID (OrgID/LocID). This 9 digit unique ID is issued as part of the OMS registration process.
- Using a combination of both the organisation name and country

Once the search is executed, the results are displayed in pipe delimited format with the following details:

- Language
- Company Name
- Address Line 1
- City
- Country

**Note**: The contents and structure is entirely dependent on the data present in OMS; given the early stage of OMS it is likely that not all data will be available as required. If data is missing or corrections are required; these need to be managed through the OMS change management process. Refer to the following link for further information: [http://spor.ema.europa.eu/omswi/#/viewDocuments](http://spor.ema.europa.eu/omswi/#/viewDocuments)
Once the OMS record has been selected all address related fields will be populated with the exception of the telephone and email. These details are held in OMS on the company level and the information required in the eAF is required for the procedure specific contact.

Once the OMS record has been selected all address related fields will be populated with the exception of the telephone and email. These details are held in OMS on the company level and the information required in the eAF is required for the procedure specific contact.

There is also the possibility to enter previously selected OMS addresses without having to perform a search on each individual entry; further aiding entry of organisation address fields, and can be illustrated as follows:

If the service is temporarily unavailable or matching data is not available the following error messages is displayed:
In case such as this, please save and close the form and reopen. If this does not help, please raise a ticket with the EMA service desk. In urgent cases, you may proceed and complete the address data manually.

**File Naming Convention**

For human medicinal products the file name will be `common-form-var.pdf`. The variable part should be used as outlined in the file & folder naming convention of the updated eCTD validation criteria version 6.1. NeeS validation criteria version 4.1. In case you have to annex parts from the Classification Guideline for variations, this should become part of the ‘var’- section, e.g. `common-form-annex-classgl.pdf`.

Recommended usage of the variable part of the file name in this section:

```
cc-form-eaf-var.pdf
cc-form-annex-var.pdf
```

In case of veterinary submissions please consult the respective guidance.

**Rendering the eAF PDF file for eCTD purpose**

Be aware of the settings for optimising the PDF file in accordance with the eCTD specifications. Make sure, that the line “Document Processing” is ticked on (as highlighted below) to allow full text index with catalogues and managing embedded indexes.

**Validating the form**

You can click the **Validate Form** button on the last page of each of the eAFs as soon as you open the document, however it should be noted that this will make filling in the form slower as the validation is performed continuously. Once the forms are validated all mandatory fields are highlighted (in yellow or
Validation can be performed as often as needed. The resulting list will provide links to the respective section where corrections or additional entries are needed.

If you are providing a separate annex to the application form instead of entering the information directly in a particular mandatory field, enter a space, N/A (not applicable) or a full stop to bypass the current minimum validation requirements. If the field does not allow text/full stop ignore the validation error and note this in the application cover letter.

In certain cases, it might not be possible to fill in all 'mandatory' fields in the eAFs leaving some form validation errors. If the information required in such fields is provided via an annex for example, or the fact that the information is not available is mentioned in the cover letter this doesn't normally cause any issues during content validation phase. However, if information required in the mandatory section is not filled in and no annex is provided a content validation issue might be triggered and the application cannot be processed.

The form validation is simply a feature that enables use of business rules and guides the MAA/MAH to fill in the form correctly to avoid content validation issues once the application has been submitted.

The validation errors are not visible in the form after it is locked and signed, however, the number of remaining errors will be displayed in the validation screen of the locked form.

Validating the form before entering the data might affect the form performance by making data entry slower – consider if you wish to validate the form, to highlight mandatory fields, before you start data entry.

**Note:** Validation rules are imposed to ensure that a good quality submission is enabled for all concerned parties. The validation rules are not linked to eCTD, NeeS or VNeeS validation rules and in some cases, for example when separate annex is used, it is acceptable to have validation error in the form which does not lead to business validation issues.

Applicants are encouraged to contact EMA technical help [EMA service desk](mailto:ema.service.desk@ema.europa.eu) if currently implemented business rules should be reviewed and/or changed.

If you have any questions, comments or proposals for a best practice solution based on your requirements, please send these to [EMA service desk](mailto:ema.service.desk@ema.europa.eu) for consideration.

**Signature**

In regard to the requirements of signing the application form, EMA and national competent authorities may have different legal obligations. Consult their respective websites. Additional information will be provided by CMDh and CMDv.

Up to now the effect of inserting an image which normally is an image of a relevant signature or an image of a text snippet stating that the form was signed by the person authorised by the applying company can be used as well, (e.g. stating “This form was approved/authorised following company policies by [Mr. Nick Name; Head of Reg. Affairs] with authorisation to sign. The signature is in file.”) The ‘signature’ image is used to lock the application form to avoid any further data manipulation. This image will not work as a digital advanced or qualified electronic signature nor can replace requirements of wet signed forms.

Brief instructions how to insert an image are contained within the tooltip for all signature fields within the eAFs. In order to ensure that the image is displayed accurately, follow the recommendations below:

<table>
<thead>
<tr>
<th>Unit of Measurement</th>
<th>Width</th>
<th>Height</th>
</tr>
</thead>
<tbody>
<tr>
<td>centimetres</td>
<td>12.70</td>
<td>2.54</td>
</tr>
</tbody>
</table>
Note: Digital signatures (as opposed to scanned signatures) are not currently within the scope of this project.

Important note: The inclusion of the signature (image) will lock the form and prevent further data entry. Therefore, the insertion of that image should be the very last step completing the form. It is strongly recommended to always save an un-locked version of the form and to execute the validation of the form prior to including the signature image. However, export of the xml file and re-import into a new eAF pdf file will work as well.

Important note: Adobe Sign or other digital signature tools must not be used to sign the eAF. This will impact the functioning of the form and may lead to rejection of your submission.

There is no need to use qualified signatures for eAFs submitted to the EMA for Centralised Procedure applications. The eAF does not change the wet signature requirements at the NCAs. Please check the national requirements for wet signatures to avoid validation issues.

In DCP/MRP an AF signed by multiple responsible persons is needed for communication with specific Authorities (could be initial submission or renewal or variation). Ideally provide a single contact point. For those NCAs that require multiple contact persons include a separate annex with the contact details.

Saving the form

The filename format for human submissions is the same as for the paper form and is detailed in the latest version of the EU Module 1 Specification EU Module 1 Specification (Appendix 2: Directory / File Structure for Module 1 (Sequential Number 9)). Also for veterinary submissions the requirements for filenames do not change with introduction of the eAF.

The eAF form (.pdf) itself contains the xml data. This document should be included within the CTD structure in folder 1.2. In the VNeeS dossier structure the correct location is in folder “1a- admin-info”. Do not include the raw xml extraction separately (see here for more details).

It is strongly recommended to save the form before locking the form. You might need to use the unlocked version to update the application form in case of business validation issues when updated application form is requested. In addition, you can re-use the file for e.g. a new variation of the same product. As an alternative and independent from locking the form, you are also able to export the XML data and import them in an empty form and correct or modify the data then.

Note: If the form has been locked with a signature image, this image will be exported and imported back. The eAF will remain locked.

To save the form, click **Save Form** at the end of the form or press Ctrl + S . Note that if you have not saved it to a specific location, the **Save As** option is displayed prompting you to save in a particular folder other than the default location.

Note: When a signature file is attached to the eAF it will be locked and no further changes are possible (with the exception of the additional signatory section, where only this section is locked).

**MAA FORM (human)**

On the following pages technical information with regard to the human marketing authorisation application form is provided. Additional information related to the veterinary form as well as related to the variation and renewal form will be provided in a separate section thereafter.
Administrative Data

Declaration and Signature

A screenshot is provided to illustrate some principles in this section.

**APPLICATION FORM: ADMINISTRATIVE DATA**

The application form is to be used for an application for a marketing authorisation of a medicinal product for human use submitted to (a) the European Medicines Agency under the centralised procedure or (b) a Member State (as well as Iceland, Liechtenstein and Norway) under either a national, mutual recognition procedure or decentralised procedure.

*Usually a separate application form for each strength and pharmaceutical form is required. For centralised procedures a combined application form is acceptable* (information on each pharmaceutical form and strength should be provided successively, where appropriate).

**DECLARATION AND SIGNATURE**

Product (invented) name: Ibuprofen 200 mg Tablets

Pharmaceutical Form: Tablet

Strength: 200

Units: mg

Active Substance: Ibuprofen (Lysine)

*Populate data in sections 2.1.2, 2.2.1 and 2.6.1*

**Product (Invented) name**

The form allows one product name to be provided. In the text field 250 characters can be used. In case of different names and marketing authorisation holders in the concerned member states a separate list needs to be appended to the application form in Annex 5.19. However, for MAA for MRP/DCP there should be one common application form for each form or strength but for all member states involved.

**Pharmaceutical form**

The pharmaceutical form should be described as in the current version of standard terms from the Ph. Eur. provided by the EDQM as also displayed via SPOR RMS controlled vocabulary list. Only the full term should be mentioned (not the short term).

Keying in the first character the term begins with and it will display the list in alphabetical order. Use the mouse or the down arrow button to navigate to the correct term. Press enter or click the left mouse button to select the term.

If the correct term is not available use an appropriate alternative instead. Usually, new pharmaceutical form terms can be required in advance by the agency responsible to run the procedure of the new marketing authorisation application.

**Strength(s)**

The strength(s) will be entered in a structured way. Consider regulatory requirements relating to the rules on naming of combination products. The units of measurement are selected from a controlled list according to standard terms as provided by EDQM (For selection the term name its first character is being used to display the list). The active ingredient data fields need to be duplicated as necessary.
**Product (invented) name:** Ibucafego 200 mg / 20 mg orodispersible tablets

**Pharmaceutical form(s):** Orodispersible tablet

<table>
<thead>
<tr>
<th>Strength:</th>
<th>Units</th>
</tr>
</thead>
<tbody>
<tr>
<td>200</td>
<td>mg</td>
</tr>
</tbody>
</table>

*For numeric values, please use the full stop as the decimal separator. i.e. 0.002, rather than 0,002*

**Full name of the active substance(s) (including salt or hydrate, if applicable):**

- **IBUPROFEN D,L-LYSINE**

  *Note: for active substances presented in the form of salt or hydrate, the expression of strength should be based on base/active moiety*

ADD ACTIVE SUBSTANCE(S)

<table>
<thead>
<tr>
<th>Strength:</th>
<th>Units</th>
</tr>
</thead>
<tbody>
<tr>
<td>20</td>
<td>mg</td>
</tr>
</tbody>
</table>

*For numeric values, please use the full stop as the decimal separator. i.e. 0.002, rather than 0,002*

**Full name of the active substance(s) (including salt or hydrate, if applicable):**

- **CAFFEINE**

  *Note: for active substances presented in the form of salt or hydrate, the expression of strength should be based on base/active moiety*

ADD ACTIVE SUBSTANCE(S)
Active Substance(s)

Use the drop-down menu to select the active substance. The dropdown menu also includes a dictionary.

Type in minimum of three characters from the name of the active substance name and click search. Enter more characters to receive more accurate results. Scroll through the list or use the arrow-down-button of the keyboard and select the correct name. Confirm the selection by clicking **OK**.

The selected substance name will be displayed. **Click** the **OK** button to close the section. For corrections “Add Active Substances” needs to be activated and opens the dialogue again.

To select another active substance, click in the add new substance section and open the dialogue by clicking **Add Active Substances**. Do this for each additional active substance.

The example above displays the case of two active substances.

Once the list is complete **click Populate data** to copy to all similar sections.
**Note**: Other similar sections cannot be filled if this first one is not completely populated.

**Note**: Workaround solution for entering formatted text using rtf format in Word or Outlook and copy pasting the edited text to eAF does not work in the Initial MAA form when the details in sections 2.1.2, 2.2.1 and 2.6.1 are populated from 'Declaration' section. If you require special characters in these sections, please add an annex and mention this on the cover letter.

Select the **Populate data in sections 2.1.2, 2.2.1 and 2.6.1** button and the form will copy data into each respective section with the exception of the Active Substance field in section 2.2.1 only. Users need to manually enter, and select an active substance for this field.

**Base/Active moiety**

Users may also provide the base/active moiety details of the active substance. This should only be added in this section if different to the active substance, serving to specify the strength of the pharmaceutical preparation and if the substance is included in the product as a salt or hydrate:

The class (type) of the substance should be selected from the proposed catalogue.

<table>
<thead>
<tr>
<th>Substance type</th>
<th>Chemicals</th>
</tr>
</thead>
<tbody>
<tr>
<td>IBUPROFEN (LYSINE)</td>
<td></td>
</tr>
<tr>
<td>Base/active moiety of the active substance(s) (if different from above)</td>
<td></td>
</tr>
<tr>
<td>IBUPROFEN</td>
<td></td>
</tr>
</tbody>
</table>

**Applicant**

The applicant address details should be selected from SPOR OMS organisation dictionary as outlined in the Providing OMS details section.
One of the address lines presented can be selected and its selection need to be confirmed by clicking Select or Select/Close.

All available details will be retrieved from OMS:
Personal details like telephone and e-mail address are not available in OMS and need to be added as appropriate.

**Person confirming fees will be/ have been paid, on behalf of the Applicant**

The following fields must be completed in accordance to the letter of authorisation as detailed in the user guidance available for human medicinal products at CMDh and for veterinary medicinal products at CMDv. CMDv. However, the company address details can be copied from the previous section by clicking the Copy contact details button from previous section button.

1. **Type of application**

The following examples describe the options to complete the form according to the planned procedure. Selecting one of the round boxes will add further lines while changing the selection will hide the lines as appropriate for the respective procedure.

1. **TYPE OF APPLICATION**

   *Note: The following sections should be completed where appropriate.*

1.1 **THIS APPLICATION CONCERNS**

   1.1.1 A CENTRALISED PROCEDURE
   
   (according to Regulation (EC) No 726/2004)

   1.1.2 A MUTUAL RECOGNITION PROCEDURE

   (according to Article 28(2) of Directive 2001/83/EC)

   1.1.3 A DECENTRALISED PROCEDURE

   (according to Article 28(3) of Directives 2001/83/EC)

   1.1.4 A NATIONAL PROCEDURE
1.1. This application concerns

In this case the centralised procedure is selected as an example how the section will be expanded depending from the selected procedure type.

This example is for human products specifically, for details of the veterinary products application form, please follow the link.

1.1.1 A CENTRALISED PROCEDURE
(according to Regulation (EC) No 726/2004)
- « Mandatory scope » (Article 3(1) of Regulation (EC) No 726/2004)
- «Generic of a Centrally Authorised Medicinal Product »
- « Marketing Authorisation including paediatric indication »
  (Article 29 of Regulation (EC) No 1901/2006)
- « Paediatric Use Marketing Authorisation (PUMA) »
  (Article 31 of Regulation (EC) No 1901/2006)

Date of acceptance/confirmation by CHMP: 
EMA Product number: 

In case of Advanced Therapy Medicinal Products

<table>
<thead>
<tr>
<th>CAT Rapporteur</th>
<th>Title</th>
<th>First name</th>
<th>Surname</th>
</tr>
</thead>
<tbody>
<tr>
<td>CAT Co-rapporteur</td>
<td>Title</td>
<td>First name</td>
<td>Surname</td>
</tr>
<tr>
<td>CHMP Co-ordinator</td>
<td>Title</td>
<td>First name</td>
<td>Surname</td>
</tr>
<tr>
<td>CHMP Co-ordinator</td>
<td>Title</td>
<td>First name</td>
<td>Surname</td>
</tr>
<tr>
<td>PRAC Rapporteur</td>
<td>Title</td>
<td>First name</td>
<td>Surname</td>
</tr>
</tbody>
</table>

The CAT-Rapporteur is only assigned in case of Combined Advanced Therapy Medicinal Products. In other cases, the selection of rapporteurs will be adjusted as appropriate.
1.1.1. A Centralised Procedure

For extension applications as indicated in section 1.3, if the corresponding original eligibility basis no longer exists. Only a Centralised Procedure should be indicated, leaving the eligibility basis tick boxes blank. The eAF does not support this very rare case of difference as details of the CHMP acceptance are required due to validation rules. (A workaround might be explained in the Q&A document if necessary.)

1.1.2. A Mutual Recognition Procedure

For a mutual recognition procedure, the Reference Member State and details of that national authorisation need to be added. Concerned Member States can be added line by line or all in one go. Type in the first character of the Member States’ name. Or use the down the drop-down menu. Click the “+” button for a next line or hit return to confirm the selection.

In case of Repeat-use Procedure the wave information is no longer required.
1.1.3. A Decentralised Procedure

There is no specific technical information to be considered.

1.1.4. A National Procedure

There is no specific technical information to be considered.

1.2. Orphan Medicinal Product Information (human only)

If your product is an orphan medicinal product, provide the below details. Tick **Yes** to display the data fields:
### 1.2 ORPHAN MEDICINAL PRODUCT DESIGNATION

1.2.1 HAS ORPHAN DESIGNATION BEEN APPLIED FOR THIS MEDICINAL PRODUCT?

<table>
<thead>
<tr>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Orphan designation procedure number:

- Pending
- Orphan Designation Granted
- Orphan Designation Refused
- Orphan Designation Withdrawn

1.2.2 INFORMATION RELATING TO ORPHAN MARKET EXCLUSIVITY

Has any medicinal product been designated as an Orphan medicinal product for a condition relating to the indication proposed in this application?

<table>
<thead>
<tr>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Please specify the EU Orphan Designation Number:

Has any of the designated orphan medicinal product(s) been granted a marketing authorisation in the EU?

<table>
<thead>
<tr>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Please specify:

<table>
<thead>
<tr>
<th>Therapeutic indication(s)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Product (Invented) name</td>
<td></td>
</tr>
<tr>
<td>Pharmaceutical form(s)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Strength(s)</th>
<th>Units</th>
<th>Name of the marketing authorisation holder</th>
<th>Marketing authorisation number</th>
<th>Procedure number for MRP/DCP (if applicable)</th>
<th>Date of authorisation</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Is the medicinal product, subject of this application, considered as "similar" to any of the authorised orphan medicinal product(s) 
(as defined in Article 3 of commission regulation (EC) no 847/2000)?

- Yes (modules 1.7.1 and 1.7.2 to be completed)
- No (module 1.7.1 to be completed)

### 1.3. Application for a change to existing marketing authorisation leading to an extension as referred to in Annex I of Regulation (EC) no 1234/2008, or any national legislation, where applicable?

There is no specific technical information to be considered.

### 1.4. This application is submitted in accordance with the following article in Directive 2001/83/EC as amended

There is no specific technical information to be considered.

### 1.5. Consideration of this application requested under the following article of Directive 2001/83/EC or Regulation (EC) No 726/2004

There is no specific technical information to be considered.

### 1.6. Requirements according to Regulation (EC) Nº 1901/2006 (‘Paediatric Regulation’)

There is no specific technical information to be considered.
2. Marketing Authorisation Application

2.1. Names(s) and ATC code

2.1.1. Proposed (invented) name of the medicinal product in the European Union / Member State/Iceland/Lichtenstein/ Norway

The information is identical to the one in section ”Declaration and signature” and has to be populated automatically (see Section 1.1.1).

If the box is ticked like this an Annex 5.19 need to be provided.

2.1 NAME(S) AND ATC CODE

2.1.1 Proposed (invented) name of the medicinal product in the European Union/Member State/Iceland/Lichtenstein/ Norway:

Ibucetegro 200 mg / 20 mg Tablets

(value populated from the ”Declaration” section.)

[ ] If different (invented) names in different Member States are proposed in a mutual recognition or decentralised procedure, these should be listed in

(Annex 5.19)

This field appears only in case of MRP or DCP selected in section 1.2 or 1.3. The annex is not integrated into the form but the required list should be added as a separate PDF file to the submission.

Attachments to the form should be included as per the currently approved processes. Annexes to the application form should always be included in section 1.2 of EU Module 1.

2.1.2. Active substance(s)

The declaration of the active substance is populated automatically if the button in section 1 has been clicked.

Any changes you want to apply must to be executed in section 1 first and this in turn correctly populates this section.
Section 2.1.2 being populated with above mentioned details: Ibucafeo 200 mg / 20mg

### NAME(S) AND ATC CODE

2.1

2.1.1 Proposed (invented) name of the medicinal product in the European Union/Member State/ Iceland/ Liechtenstein/ Norway:

Ibucafeo 200 mg / 20 mg orodispersible tablet

(Value populated from the "Declaration" section.)

If different (invented) names in different Member States are proposed in a mutual recognition or decentralised procedure, these should be listed in

(Annex 5.19)

2.1.2 Active substance(s)

Note: * active substance should be indicated here as full substance. If the substance is included in the product as a salt or hydrate, the corresponding base/active moiety should be indicated in the additional field:

Name should be based on the following order of priority: IINN*, Ph.Eur., National Pharmacopoeia, common name, scientific name.

(The value of the active substances field has been populated from "Declaration" section.)

<table>
<thead>
<tr>
<th>Full name of the active substance(s) (including salt or hydrate, if applicable)</th>
</tr>
</thead>
<tbody>
<tr>
<td>IBUPROFEN (LYSINE)</td>
</tr>
<tr>
<td>Base/active moiety of the active substance(s) (if different from above)</td>
</tr>
<tr>
<td>IBUPROFEN</td>
</tr>
<tr>
<td>CAFFEINE</td>
</tr>
<tr>
<td>Base/active moiety of the active substance(s) (if different from above)</td>
</tr>
</tbody>
</table>

Substance type: (e.g. chemical substance, recombinant biological substance)
2.1.3. Pharmacotherapeutic group

The most complete code corresponding to the claimed therapeutic use of the product should be given. Please use current ATC codes. Consequently, this section should be duplicated where needed. To display the list, at least three characters need to be inserted. The list starts with the next available code based on your entry.

The two fields ATC Code and Group are linked and should be both completed.

Note: The group text field is limited. You may have to reduce the text appropriately.

It is advisable to know the ATC code in advance as the search tool may not display the entire details of each code.

2.2. Strength, pharmaceutical form, route of administration, container and pack sizes

2.2.1. Strength and pharmaceutical form (use current list of standard terms – European Pharmacopeia)

If the values of the Pharmaceutical form, Strength and Active Substance field have been populated from the Declaration section” it is not possible to edit the following data fields. If you need to correct an error, go back to Declaration section.
Search and select the active substance(s) in the Declaration’ section and populate the sections where active substance is required by **clicking Populate data in section 2.2.1 and 2.6.1.**

### 2.2 STRENGTH, PHARMACEUTICAL FORM, ROUTE OF ADMINISTRATION, CONTAINER AND PACK SIZES

#### 2.2.1 Strength and pharmaceutical form (use current list of standard terms - European Pharmacopoeia)

*(The values of the following fields have been populated from "Declaration" section.)*

<table>
<thead>
<tr>
<th>Pharmaceutical Form:</th>
<th>Orodispersible tablet</th>
</tr>
</thead>
<tbody>
<tr>
<td>Strength:</td>
<td>Units:</td>
</tr>
<tr>
<td>200</td>
<td>mg</td>
</tr>
</tbody>
</table>

*For numeric values, please use the full stop as the decimal separator. i.e. 0.002, rather than 0,002.*

**Active substance(s) (as used for expression of strength*)**

- IBUPROFEN

*Note: * for active substances presented in the form of salt or hydrate, the expression of strength should be based on base/active moiety*

**Add Active Substance(s) or Base/active moiety**

<table>
<thead>
<tr>
<th>Strength:</th>
<th>Units</th>
</tr>
</thead>
<tbody>
<tr>
<td>20</td>
<td>mg</td>
</tr>
</tbody>
</table>

*For numeric values, please use the full stop as the decimal separator. i.e. 0.002, rather than 0,002.*

**Active substance(s) (as used for expression of strength*)**

- CAFFEINE

*Note: * for active substances presented in the form of salt or hydrate, the expression of strength should be based on base/active moiety*

**Add Active Substance(s) or Base/active moiety**

If a salt/ester/maleate/monohydrate etc. form is required, this can be added via the corresponding **base/active moiety field** as detailed in **Base/Active moiety** section.

#### 2.2.2 Route(s) of administration (current list standard terms - European Pharmacopoeia)

Use the dropdown field to open the search menu. The dropdown includes the current list of standard terms included in the List of Standard Terms for pharmaceutical dosage forms, routes of administration and containers published by the **EDQM / RMS**.

Repeat the routes field using the “+” and/or “-” buttons.
2.2.3. Container, closure and administration device(s)

Include a description of material from which it is constructed. Use the current list of standard terms - European Pharmacopoeia.

Provide details for each of the pack sizes that are planned for marketing. The package sizes fields are can be repeated using the "+" / "-" button.

The material field is a free text but it is advisable to use known standard abbreviations for chemical names, such PVC or HDPE.
2.2.4. Medical Devices

The medical product incorporates, as an integral part, one or more medical devices within the meaning of Article 1(2)(a) of Directive 93/42/EEC or one or more active implantable medical devices within the meaning of Article 1(2)(c) of Directive 90/385/EEC. There is no specific technical information to be considered.

2.3. Legal status

The dispensing status applies to all Member States the product is authorised to be marketed. For convenience all Member States selected according to section 1.1 can be added or removed by clicking the Add Selected or Remove All buttons.
2.3 LEGAL STATUS

2.3.1 Proposed dispensing/classification
(Classification under Article 1(19) of Directive 2001/83/EC)
- Subject to medical prescription (Complete 2.3.2)
- Not subject to medical prescription (Complete 2.3.3 & 2.3.4)

The adjustment of the list can easily be achieved by deleting single Member States clicking the - button.

2.4. Marketing authorisation holder / contact persons / company

Select from 2 options: Centralised Procedure and National Procedures in section 1.1. It is not possible to change the selection in this section. Copy address details from the Declaration section by clicking on one of the following buttons.

2.4.1. Proposed responsible marketing authorisation holder/person
In the second case the address details will be assigned to the respective Member State. To simplify data entry a button to insert contact details from Declaration section is available. To add the Member States selected in that section click Add Selected.
2.4.1 Proposed marketing authorisation holder/person legally responsible for placing the product on the market in the European Union/each Member State

- Centralised procedure
- National procedure including mutual recognition/decentralised procedure

For MRP/DCP/National procedure; The Member State field allows multiple Member States to have the same marketing authorisation holder contact person, or alternatively to show that one or more Member States have different marketing authorisation holder contact persons.

**Note:** This field is not mandatory and it will be expected that all relevant member states have the same marketing authorisation holder contact person.

Additionally, details of proof of payment can be entered regardless of the procedure.

If the fees have not been paid in advance and an invoice is going to be sent select No and indicate the billing address (even if it has not yet been relevant to pay a fee as it will be invoiced later).

For a Centralised Procedure; either select ‘EU’ from the term list or leave the Member state field empty.

2.4.2. Person/company authorised for communication on behalf of the applicant during the procedure

No specific technical guidance is necessary.
2.4.3. Person/company authorised for communication  

No specific technical guidance is necessary.

2.4.4. Summary of the applicant pharmacovigilance system

For the section 2.4.4 Summary of the pharmacovigilance system, in a community procedure with more than 1 MAH Qualified Person in EEA for Pharmacovigilance can be increased for more than one QPPV. Also the location of the Pharmacovigilance system master file can be multiplied independently. If the location is the same for all Member States, the Member states need to be added in the first box. If this is not the case, the entire section needs to be copied. In this case section 2.4.4 needs to be repeated as different PV master files will be maintained. For each system the QPPV may be identical.

2.5. Manufacturers

Note: All manufacturing and control sites mentioned throughout the entire dossier must be consistent regarding names, detailed addresses and activities.

In this section the address fields offer a possibility to enter two addresses if the administrative address differs from the manufacturing site:

2.5.1. Authorised manufacturer(s) (or importer(s)) responsible for batch release in the EEA

Subsections are defined to describe different roles:

- Authorised manufacturer(s) (or importer(s)) responsible for batch release in the EEA in accordance with Article 40 and Article 51 of Directive 2001/83/EC (as shown in the package leaflet and where applicable in the labelling or Annex II of the Commission Decision)
- Official batch release for Blood products and Vaccines
- Details of the Official Medicines Control Laboratory (OMCL) or laboratory designated for the purpose of official batch release (in accordance with Articles 111(1), 113, 114(1)-(2) and 115 of Directive 2001/83/EC as amended)
- Contact person in the EEA for product defects and recalls
- Batch control Testing arrangements

On top of the sub-section a free text field is available so applicants who have multiple manufacturers doing batch releases can include details of, for example, which packaging the manufacturer is responsible for. This is an optional field that can be left blank it is not required.

The following screens illustrate the principle of the two options offered for all address fields in section 2.5 in case the administrative address and the manufacturing facility address is identical or different:

Option # 1:- Administrative and manufacture address(es) are the same

The fields related to telephone, e-mail can be duplicated in order to indicate more than one number in case the administrative and operating addresses differ:
Option # 2:- When the administrative address and manufacture address are different:

For additional authorised manufacturer’s data fields can be repeated, where required, using the “+” / “-” buttons:

Any manufacturer responsible for batch release in the EEA should be listed under section 2.5.1 of the application form. This is the only section where this information should be provided. If the site responsible for batch release in the EEA is also involved in batch control testing activities, the name and address of such site should be repeated in section 2.5.1.2.
2.5.2. Manufacturer(s) of the medicinal product and site(s) of manufacture

A free text field is included to add a description of the partial product (e.g. vial with solvent, vial with powder, solvent etc. can be included to indicate which part of the product a specific manufacturer produces. This field is optional.
Address details can be copied from section 2.5.1.a if identical or if it is more convenient to make minor corrections afterwards.

For sites in the EEA, the manufacturing authorisation number should always be provided. In addition, either a copy of the authorisation (tick box) or the EudraGMDP reference number should be provided. If neither the copy nor the EudraGMDP number are provided a validation error is displayed.

Note: Including manufacturing sites of any diluent/solvent presented in a separate container but forming part of the medicinal product, quality control/ in-process testing sites, immediate and outer packaging and importer(s). For each site provide the relevant information.

If the site is outside the EEA provide the following information:
The reasoning from a regulatory point of view reads as follows: Release testing of the finished product is part of Quality testing. This activity is only linked to sites performing Batch Control testing arrangements in relation to the Batch Release of the product as per requirements of Article 51 of Directive 2001/83/EC. As such a site may perform both release testing under 2.5.1.2 and “normal” QC-FP activities under 2.5.2 which are not linked to the batch release. In this case, the site(s) will be listed twice i.e. under each section. However, if the site only performs one or the other quality control testing only, the site(s) will then need to be listed in the relevant section depending on the QC-FP activity.

Testing arrangements in relation to the Batch Release of the product. Sometimes, sites perform both kinds of testing activities. However only sites located in the EEA or where an MRA or ACAA arrangement is in place can be listed in 2.5.1.2. Third country sites (USA and any other country outside the EEA/MRA/ACAA) cannot perform this activity and should therefore not be listed in 2.5.1.2. These sites are only authorised to perform QC-FP activities not related to the Batch Release.

However, only the tests carried out for the products in the application should be listed here. Therefore, you should not mention all possibilities as is stated in Manufacture License for company (if possible to find them there).
2.5.3. Manufacturer(s) of the active substance(s) and site(s) of manufacture

All manufacturing sites involved in the manufacturing process of each source of active substance. For each site provide the relevant information.

<table>
<thead>
<tr>
<th>Active Substance</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

(The values of the active substances field has been populated from "Declaration" section, hence no search button available. Please click the drop down button to see the list.)

Do you have a separate admin and manufacturer address?  
[ ] Yes  
[ ] No

Please select organisation from SPOR OMS to autofill address details. If the organisation is not found or the address details are not correct, please visit the OMS page in the SPOR portal for more information:  
http://spor.omm.europa.eu/oms/F

The active substance is selected from previously selected list (Section 2.1). The values of Active Substance field have been populated from “Declaration’ section.
Use the drop-down menu to select between the manufacturing steps performed.

The dictionary for processing of medicinal products and for manufacturing steps are linked to the guidance document included in the eAF itself next to this field where more information can be sought from.

These are the Interpretation Documents for MIAs and GMP certificates. These are part of the 'Compilation of Union Procedures on Inspections and Exchange of Information', which is published on the EMA external website (see pages 144-173). E.g. the role 'Manufacture of the finished product' or "Manufacturing of the VMP" are covered by the term 'Processing of medicinal product'.

The contents of the controlled vocabulary are coming directly EUTCT (for substances only) as well as RMS (for all other lists) and the terms have been decided by the European inspectors from documents issued from Inspection.

Additional information in regard to inspections, suitability of Pharm. Eur. Certificates or information on ASMF can be entered if the respective box ‘yes’ is ticked.

2.5.4. Contract companies used for clinical trial(s) (including bioavailability and bioequivalence studies) included in the application or used for the validation of blood product manufacturing processes.

For each contract company, state where analytical tests are performed and where clinical data is collected and open data fields by clicking the Add Study button.
In cases where multiple studies have been performed by only one contract company all study titles can be keyed in by repeating the first section.

Company details are grouped and details of the tasks related to the study can be provided. In case multiple contract companies have been involved the address fields and details of the tasks can be repeated using the "+" / "-" buttons.

2.6. Quantitative and Qualitative Composition

2.6.1. Qualitative and Quantitative composition in terms of the active substance(s) and the excipient(s)

The chosen active substance(s) is/are automatically displayed in section 2.6.1 on the 'Name of active substance field(s)’. Additional information on the active substance including all excipients in a separate list can be added.

To interpret the composition correctly the reference of counting must be stated in the first line. All quantities of substances are referring to a defined quantity of the specified pharmaceutical form, e.g. 1 (unit) of tablets or 100 (ml) of a solution.
2.6 QUALITATIVE AND QUANTITATIVE COMPOSITION

2.6.1 Qualitative and Quantitative composition in terms of the active substance(s) and the excipient(s)

In centralised procedures multiple strengths can be included on one application form. For this purpose the following frame of strength needs to be duplicated. In case of national procedures only 1 strength per pharmaceutical form can be mentioned in 1 MAA form.

In the free text field, add a qualifying like ‘calculated as’. This text field will also serve for an additional explanation to separate the filling of a capsule from the capsule shell or clustering all ingredients of the printing ink.

The quantity is built with an operator, a value and the unit of measure: equal to 20 mg. A reference can also be added, e.g. Pharm.Eur. If you select range as the quantity operator, the value field will be split into a lower and upper value.

The quantity operator ‘quantity sufficient’ is defined as adding enough of an ingredient to achieve a specific final volume or total weight. This term has been discussed extensively in the past and it was
agreed that ‘quantity sufficient’ was introduced as quantity operator in the eAFs to describe the limits precisely.

To express for example: “to five grams of NaCl add enough (quantity sufficient qs) water to make 100 ml”

Ingredient = water
Quantity operator = "quantity sufficient"; Value =100
Unit = "mL"

<table>
<thead>
<tr>
<th>Name of active substance</th>
<th>Quantity / Unit</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

If multiple active substances have been selected in the ‘Declaration’ section, these are automatically displayed.

Delete any unnecessary fields displaying incorrect terms using button.

**Process steps in case of a missing substance name/term**

If you need to request a missing substance to complete an eAF, submit a request for substance insertion with the corresponding SmPC using the EMA Service Desk portal.

To request a new term (e.g. pharmaceutical form or unit of measurement) or a request for an update of an existing term in order to complete the eAF, please submit a request through the SPOR Portal and provide as much supporting documentation as possible (e.g. name of the product concerned, SmPC, etc.). Please note you need to be registered with SPOR prior to submission of change requests: The user guide for managing referential and organisation data in eAF is available here.

A provisional term may be added to the list within 5 working days; however, please note that there is a possibility that the term might not be approved in future. More information on how to request additional terms in eAF can be found in the RMS Web User Manual available here.

In case of declaration of overages it is mandatory to complete this section:

**Details of any overages should not be included in the formulation columns but stated below:**

<table>
<thead>
<tr>
<th>Active Substance</th>
<th>Overage</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Excipient</th>
<th>Overage</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Press the “+” button and select from the drop-down menu the substance as included in the composition then add the overage value. Use a full stop to indicate decimal numeric values.

2.6.2. List of materials of animal and/or human origin contained/ used in the manufacturing process of the medicinal product?

There is no specific technical information to be considered.

2.6.3. Is an EMEA certificate for a Plasma Master File (PMF) issued or submitted in accordance with Directive 2001/83/EC Annex I, Part III, being used for this MAA?

There is no specific technical information to be considered.

2.6.4. Does the medicinal product contain or consist of Genetically Modified Organisms (GMOs) within the meaning of Directive 2001/18/EC?

There is no specific technical information to be considered.

3. Scientific advice

3.1. Was there formal scientific advice(s) given by EMA for this medicinal product?

There is no specific technical information to be considered.

3.2. Was there scientific advice(s) given by Member State(s) for this medicinal product?

These sections may be replicated where needed.

4. Other marketing authorisation applications

There is no specific technical information to be considered.

5. Annexed documents (where appropriate)

There is no specific technical information to be considered.
MAA FORM (veterinary)

On the following pages, technical information with regards to the veterinary marketing authorisation application form is provided. To avoid duplication of information reference is provided to the human MAA form as appropriate. Information related to the variation and renewal form will be provided in a separate section thereafter.

Administrative data

For details on this section please refer to the identical section of the MAA form for human medicinal products.

Declaration and signature

The following example is provided to illustrate some principles in this section which are entirely the same human medicinal products.
1. **Type of application**

The following examples describe the options to complete the form according to the planned procedure. Ticking one of the round boxes will add further lines as appropriate for the respective procedure. Changing of the selection will hide the lines but addition different ones according to the other procedure selected.

### 1. TYPE OF APPLICATION

**Note:** The following sections should be completed where appropriate.

#### 1.1 THIS APPLICATION CONCERNS

- **1.1.1 A CENTRALISED PROCEDURE** (according to Regulation (EC) No 726/2004)
- **1.1.2 A MUTUAL RECOGNITION PROCEDURE** (according to Article 32(2) of Directives 2001/82/EC)
- **1.1.3 A DECENTRALISED PROCEDURE** (according to Article 32(3) of Directive 2001/82/EC)
- **1.1.4 A NATIONAL PROCEDURE**

#### 1.1. This application concerns

In this case the centralised procedure is selected as an example how the section will be expanded depending from the selected procedure type.

This example is for veterinary products specifically, for details of the human products application form, please follow the [link](#).

- **1.1.1 A CENTRALISED PROCEDURE** (according to Regulation (EC) No 726/2004)
  - "Mandatory scope" (Article 3(1))
  - "Optional scope" (Article 3(2))
  - "Generic of a centrally authorised veterinary medicinal product" (Article 3(3))

<table>
<thead>
<tr>
<th>CVMP Rapporteur</th>
<th>Title</th>
<th>First name</th>
<th>Surname</th>
</tr>
</thead>
<tbody>
<tr>
<td>CVMP Co-rapporteur</td>
<td>Title</td>
<td>First name</td>
<td>Surname</td>
</tr>
</tbody>
</table>

#### 1.1.1. A Centralised Procedure

There is no specific technical information to be considered.

#### 1.1.2. A Mutual Recognition Procedure

There is no specific technical information to be considered.

#### 1.1.3. A Decentralised Procedure

There is no specific technical information to be considered.
1.1.4. A National Procedure

There is no specific technical information to be considered.

**1.2. Is this an application for a change to your existing marketing authorisation leading to an extension as referred to in Annex I of Regulation (EC) NO 1234/2008, or any national legislation, where applicable?**

There is no specific technical information to be considered.

**1.3. This application is submitted in accordance with the following articles in Directive 2001/82/EC**

There is no specific technical information to be considered.

**1.4. MRL status (only for food-producing species)**

![MRL Status Table](image)

Application for a Maximum Residue Limit has been made to the EMA

- Yes
- Not applicable

1 All substances contained in the product are subject to this requirement if they are pharmaceutically active in the dose in which they are administered to the animal. Excipients not included in Regulation (EU) No 37/2010 should also be listed and an appropriate justification given.
### Maximum Residue Limits (MRL) according to Commission Regulation (EU) No 37/2010

<table>
<thead>
<tr>
<th>substance(s)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>BENZYL-PENICILLIN SODIUM</td>
<td></td>
</tr>
</tbody>
</table>

#### Application for a Maximum Residue Limit has been made to the EMA

- **Yes**
- **Not applicable**

---

1. All substances contained in the product are subject to this requirement if they are pharmacologically active in the dose in which they are administered to the animal. Excipients not included in Regulation (EU) No 37/2010 should also be listed and an appropriate justification given.
The form requires excipients not included in Regulation (EU) No 37/2010 should also be listed and an appropriate justification given. If this is the case, tick “not applicable” and provide justification in the “remarks” field.

In case an MRL application has been submitted to the EMA and the procedure is still pending, tick Yes and provide details on the application including submission date in this section:

1.5. Consideration of this application is also requested under the following article in Directive 2001/82/EC or Regulation (EC) No 726/2004

There is no specific technical information to be considered.

2. Marketing authorisation application particulars

2.1. Name(s) and ATC vet code and target species

2.1.1. Proposed (invented) name of the veterinary medicinal product in the European Union / Member State/Iceland/Lichtenstein/ Norway

The information is identical to the Declaration and signature and is populated automatically.

If the box is ticked provide Annex 5.18.

This field is only displayed in the case of an MRP or DCP selected in section 1.2 or 1.3. The annex is not integrated into the form but added as a required list in a separate PDF file to the submission.

2.1.2. Active substance(s)

The declaration of the active substance is populated automatically if the button in section 1 is clicked.
2.1.3. Pharmacotherapeutic group (Please use current ATC vet code)

2.1.4. Target species

The most complete code corresponding to the claimed therapeutic use of the product should be given. Consequently, this section should be duplicated where needed.

The ATC Code (select vet specific terms) and Group fields are linked and both should be completed. It is recommended to key in the third or fourth level description. However, the description of the third or fourth level of the ATC vet code may be too long to include completely.

<table>
<thead>
<tr>
<th>Target species</th>
<th>Bovine, including buffalo</th>
</tr>
</thead>
<tbody>
<tr>
<td>Target species</td>
<td>Beef cattle</td>
</tr>
<tr>
<td>ATC Code</td>
<td></td>
</tr>
<tr>
<td>Group</td>
<td>Penicillins with extended spec</td>
</tr>
</tbody>
</table>

2.2. Strength, pharmaceutical form, route of administration, container and pack sizes

2.2.1. Strength and pharmaceutical form (use current list of standard terms – European Pharmacopoeia)

For details refer to the human products application form.

2.2.2. Route(s) of administration (use current list of standard terms - European Pharmacopoeia)

The drop-down menu includes the current list of standard terms included in the “List of Standard Terms for pharmaceutical dosage forms, routes of administration and containers” published by the EDQM / RMS. Repeat the routes if required using the “+”/ “-” buttons. Complete the section by selecting the target species again.
2.2.3. Container, closure and administration device(s), including description of material from which it is constructed. (use current list of standard terms - European Pharmacopoeia)

<table>
<thead>
<tr>
<th>Package Size 1</th>
<th>+ -</th>
</tr>
</thead>
</table>

**Note:** For mutual recognition and decentralised procedures, all package sizes authorised in the Reference Member State should be listed.

**For each container give:**

<table>
<thead>
<tr>
<th>Container</th>
<th>+ -</th>
</tr>
</thead>
<tbody>
<tr>
<td>Material</td>
<td>+ -</td>
</tr>
<tr>
<td>Closure</td>
<td>+ -</td>
</tr>
<tr>
<td>Administration Device</td>
<td>+ -</td>
</tr>
</tbody>
</table>

| 2.2.3.2 Proposed shelf life | + - |
| 2.2.3.3 Proposed shelf life (after first opening container) | + - |
| 2.2.3.4 Proposed shelf life (after reconstitution or dilution) | + - |

| 2.2.3.5 Proposed storage conditions | + - |
| 2.2.3.6 Proposed storage conditions after first opening | + - |

Provide details for each of the pack sizes planned for marketing. Repeat the package sizes fields if required using the “+”/“-” buttons as displayed in the example above.

In this example highlighted fields indicate the mandatory section to be input as a minimum. The highlight appears after clicking the validate form button at the end of the form.

The term list on Container, Closure and Administration Device will become more complete over time. Therefore, check carefully in advance whether the term you will use is provided. Otherwise, request the term as soon as possible at mdms@ema.europa.eu.

The material is a free text field, but it is advisable to use known standard abbreviations for chemical names, such PVC, HDPE, etc.
2.3. Legal status

There is no specific technical information to be considered.

2.4. Marketing authorisation holder / contact persons / company

For details refer to the human products application form.

2.5. Manufacturers

For details refer to the human products application form.

2.6. Quantitative and qualitative composition

2.6.1. Qualitative and Quantitative composition in terms of the active substance(s) and the excipient(s)

For details refer to the human products application form.

2.6.2. List of materials of animal and/or human origin contained or used in the manufacturing process of the medicinal product?

There is no specific technical information to be considered.

2.6.3. Does the veterinary medicinal product contain or consist of Genetically Modified Organisms (GMOs) within the meaning of Directive 2001/18/EC?

There is no specific technical information to be considered.

3. Scientific advice

3.1. Was there formal scientific advice(s) given by CVMP for this veterinary medicinal product?

There is no specific technical information to be considered.

3.2. Was a scientific recommendation(s) given by Member State(s) for this veterinary medicinal product?

These sections may be replicated if needed.

4. Other marketing authorisation applications

There is no specific technical information to be considered.

5. Annexed documents (where appropriate)

There is no specific technical information to be considered.
VARIATION FORM

On the following pages technical information on the variation form is provided.

1. Application for variation to a marketing authorisation

   1. APPLICATION FOR VARIATION TO A MARKETING AUTHORISATION

      ☒ Human   ☐ Veterinary

      ☒ National Authorisation in MRP/DCP
      ☐ EU Authorisation
      ☐ National Authorisation

      Variation procedure number(s)¹

      DE/H/2020/301-002/II/G/022 [+] [−]

      Reference Member State / Reference Authority for worksharing: Germany

      Concerned Member State(s)

      Add All   Remove All

      Austria [x] [+] [−]

      Estonia [x] [+] [−]

      Finland [x] [+] [−]

      Type of Application (tick all applicable options)

      ☐ Single variation
      ☒ Grouping of variations
        ☐ Including a line extension³
      ☒ Worksharing

      ☐ Type IA³
      ☒ Type IA
      ☐ Type IB unforeseen³
      ☐ Type IB
      ☒ Type II
      ☐ Type II Art. 29³

      Change(s) concern(s) (for Type IB and Type II variations only, tick all changes applicable)

      ☐ Indication
      ☐ Paediatric requirements
      ☐ Safety
      ☐ Quality
      ☐ Annual variation for human influenza vaccines
      ☐ Non-food producing target species
      ☐ Other

Details of the procedure number and involved Member States depend from the type of procedure. In case of variations to a national authorisation in MRP/DCP select the Reference Member State. In the list below all Member States or the EMA can be selected except the same Member States as already selected in the role of RMS. You may add member states line by line or click Add all to add all member states at once. To remove them all in one go by click Remove all. It is also possible to remove single member states line by line.
Select the type of variation next. In case of variations other than IA/IAIN additional information about the scope of the variation should be indicated.

Please note that the selection in this section will directly impact the scopes available in section 3 and any changes in section 1 will delete the selected scopes in section 3.

If grouping is selected in section 1, multiple scopes can be selected in section 3. It is possible to add more scopes by using the dropdown menu, by +/- buttons or using a clone button.

If single is selected in section 1, only one scope can be selected in section 3.

For example, if procedure type Type IA has been selected in section 1, only scopes applicable type Type IA will be available for selection in section 3.

In case of purely nationally authorised products involved in a work sharing procedure, the Reference Authority will be included instead of the RMS.

The selection of the MA Holder address will be supported by the SPOR Organisation Management Service as outlined in providing contact & address details.
2. Products concerned by this application

The variation form allows you to include all forms and strengths. Again, the signatures should be provided by the MAH. If different national companies are involved it is recommended to add power of attorney as required by member states appropriately.

The products involved in the variation need to be named. To allow all possibilities to be keyed in within a structured manner, this section has completely been revised. The principles of that construct are explained in the following example:

The sample displays how several products with different authorisation numbers different product names or different MAH names etc. can be added. In case the strength details are too complex, a footnote can be added to describe the strengths in more detail:

<table>
<thead>
<tr>
<th>Variation Number: 06/02/12/01/14/99B</th>
</tr>
</thead>
</table>

**Form and Strength information is provided in footnote**

### Germany

<table>
<thead>
<tr>
<th>MA Number(s)</th>
<th>Invented Name</th>
<th>MA Holder Name(s)</th>
<th>Pharmaceutical Form</th>
<th>Strength</th>
<th>Unit</th>
</tr>
</thead>
<tbody>
<tr>
<td>1234.00.00</td>
<td>Advil</td>
<td>Company</td>
<td>Tablet</td>
<td>200</td>
<td>mg</td>
</tr>
<tr>
<td>1234.00.01</td>
<td>Advil forte</td>
<td>Company</td>
<td>Tablet</td>
<td>400</td>
<td>mg</td>
</tr>
</tbody>
</table>

### Austria

<table>
<thead>
<tr>
<th>MA Number(s)</th>
<th>Invented Name</th>
<th>MA Holder Name(s)</th>
<th>Pharmaceutical Form</th>
<th>Strength</th>
<th>Unit</th>
</tr>
</thead>
<tbody>
<tr>
<td>PKN 1234</td>
<td>Advil</td>
<td>Company</td>
<td>Tablet</td>
<td>200</td>
<td>mg</td>
</tr>
<tr>
<td>PKN 1235</td>
<td>Advil forte</td>
<td>Company</td>
<td>Tablet</td>
<td>400</td>
<td>mg</td>
</tr>
</tbody>
</table>

### Netherlands

<table>
<thead>
<tr>
<th>MA Number(s)</th>
<th>Invented Name</th>
<th>MA Holder Name(s)</th>
<th>Pharmaceutical Form</th>
<th>Strength</th>
<th>Unit</th>
</tr>
</thead>
<tbody>
<tr>
<td>RVG 120024</td>
<td>Advil</td>
<td>Company</td>
<td>Tablet</td>
<td>200</td>
<td>mg</td>
</tr>
<tr>
<td>RVG 120025</td>
<td>Advil forte</td>
<td>Company</td>
<td>Tablet</td>
<td>400</td>
<td>mg</td>
</tr>
</tbody>
</table>

**Footnote**

This describes all employed strengths
3. **Types(s) of changes (s)**

Select the changes you want to submit: The variation items according to EU Commission Guidelines will be selectable from RMS using a dropdown menu **clicking Show Variation Lists**.

The selections in section 1 (single/grouping and the procedure type) is reflected above the dropdown menu to remind the user of their previous selections. It is very important to note that any change in Type of Application in section 1 will delete any selected variation in section 3.

### 3. **TYPES OF CHANGE(S)**

**Variations included in this application:** Please follow instructions below to add variation.

*Fill Section 1 of the form first, so as for the proper variations to be loaded. Navigate through the dropdown lists, in order to show the variation.*

*You can select the variation by clicking the relevant checkbox of the variation box.*

*Note: Any change in Type of Application in Section 1, will delete any selected variant.*

<table>
<thead>
<tr>
<th>Variation</th>
<th>Selected</th>
</tr>
</thead>
<tbody>
<tr>
<td>Variation</td>
<td>Show Selected Variations</td>
</tr>
</tbody>
</table>

Single Variation is being selected. You may choose only type IA variation changes and only one scope.

- A. ADMINISTRATIVE CHANGES
- B. QUALITY CHANGES
- C. SAFETY, EFFICACY, PHARMACOVIGILANCE CHANGES
- D. PMF / VAMF

Grouping of variations is being selected. You may choose variation changes of types that are selected on section 1.

- B. QUALITY CHANGES
- B.I. ACTIVE SUBSTANCE
- B.I.b) Control of active substance
- B.I.b.1) Change in the specification parameters and/or limits of an active substance, starting material / intermediate / reagent

- B.I.b.1.a) Tightening of specification limits for medicinal products subject to Official Control Authority Batch Release
- B.I.b.1.b) Tightening of specification limits
- B.I.b.1.c) Addition of a new specification parameter to the specification with its corresponding test method
- B.I.b.1.d) Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)
- B.I.b.1.e) Deletion of a specification parameter which may have a significant effect on the overall quality of the active substance
- B.I.b.1.f) Change outside the approved specifications limits range for the active substance
- B.I.b.1.g) Widening of the approved specifications limits for starting materials/intermediates, which may have a significant
- B.I.b.1.h) Addition or replacement (excluding biological or immunological substance) of a specification parameter with it
- B.I.b.1.i) Where there is no monograph in the European Pharmacopoeia or the national pharmacopoeia of a Member State

Drill down the selection to select the variation scopes. If only one option is applicable/available according to previous selections, it will be automatically ticked and cannot be manually changed.

For grouped variations there are +/- buttons and clone button to copy/add multiple scopes.

Depending on the selections, implementation date/note box will be available. If Art. 5 is applicable, the box will be automatically ticked and cannot be manually changed.
The conditions and documentation have been integrated into the scope in RMS and are now part of the scope selection. Only relevant conditions and documentation for each scope will be shown. Applicable conditions and documentation can be selected using a tick box. If any of the options is not applicable/not met, a mandatory free text field must be used to provide justification or further details. The free text fields are always available and can be used to provide additional, relevant information as previously when this information was provided as a separate annex to the application form.

Example of ‘single Type IA’

3. **TYPES OF CHANGE(S)**

**Variations included in this application:** Please follow instructions below to add variation

*Fill Section 1 of the form first, so as for the proper variations to be loaded. Navigate through the dropdown lists, in order to show the variation.*

*You can select the variation by clicking the relevant checkbox of the variation box.*

*Note: Any change in Type of Application in Section 1, will delete any selected variation!*

<table>
<thead>
<tr>
<th>Variation</th>
<th>Selected</th>
</tr>
</thead>
<tbody>
<tr>
<td>A.S.b</td>
<td>1</td>
</tr>
</tbody>
</table>

---

Single Variation is being selected. You may choose only type IA variation changes and only one scope.

**select**

A.S.b - ADMINISTRATIVE CHANGES - Change in the name and/or address of a manufacturer/importer of the finished product (including batch release or quality control testing site) - The activities for which the manufacturer/importer is responsible do not include batch release.

Procedure Types: **IA** [ ] **IB** [x]

Implement. Date: [ ] Implement. Note: [ ]

Conditions:

- [x] The manufacturing site undergoing the name and/or address change and all manufacturing operations must remain the same.

Note: [ ]

**Documentations:**

- [x] Copy of the modified manufacturing authorization, if available, or a formal document from a relevant official body (e.g. Chamber of Commerce, or if not available, from a Regulatory Agency) in which the new name and/or address is mentioned.

Note: [ ]

- If applicable, amendment of the relevant section(s) of the dossier (presented in the EU-CTD format or NTA volume 6B format for veterinary products, as appropriate), including revised product information as appropriate.

Note: [ ]

Example of Grouping of Type IB and Type II
Once you have made your selection(s) you can close the list / collapse the list to show only the selected items by clicking Show Selected Variations.

If you wish to change the selections, simply unselect the selected scope and if necessary to show the selection dropdown menu, click Show Variation Lists.

It is essential to select the scopes by ticking the Select tick box. If this is not done the scope is not selected and any change in the dropdown menu will delete the changes you have made. Always ensure that the selected scope is shown in the summary box before proceeding to select more scopes/moving to next sections.
Depending from the items you have to complete, the following table describes the present and proposed wording in the PL or SmPC or any brief description of the changes, or DUNS number of involved manufacturer or ASMF reference number. Due to the anticipated complexity this is not needed in case of work sharing or grouping procedures affecting more than one product.

**Present and proposed section – text fields**

It is possible to include formatted text, but only in the present and proposed text fields of this form. All other free text fields in the forms allow only plain text. Track-changes functionality is currently not available in interactive Acrobat forms.

The formatting can be changed based on the following rules:

Click to insert details regarding present product information in the free text field. You can change the presentation of the text. To underline, set italic or set bold, select the words and use following key combinations: CTRL+U, CTRL+I, CTRL+B on Windows and CMD+U, CMD+I, CMD+B on Mac.

Using the right mouse button, you can select Text style providing the same options: If selecting Hyperlink, the pop-up will provide more options to directly format the text or paragraph:
Alternatively, rich text (formatted) can be used by editing the text in Word™ or Outlook™ in the rtf format. Copy and paste the formatted text into the present and proposed fields.

A complex table as part of the present and proposed section in the variation eAF cannot be included. When a table is needed in the present and proposed section of the eAF you are able to include the information in separate annex included in folder 1.2 of the eCTD structure for Human applications or in the "1a-admin-info" folder of the VNeeS structure for Veterinary applications.

The annex should be attached as a separate PDF document, clearly named (for example 'ema-form-annex-presentandproposed') in the folder 1.2 or folder "1a-admin-info" for VNeeS submissions.

Text such as 'See Annex Present and Proposed' should be entered into the mandatory present and proposed fields of the eAF.

To include an image (always one image per cell) click the left mouse button into the cell. Select from your file share an image as appropriate. If the size needs to be adjusted, please provide the image as an annex as the image cannot be enlarged.

Additionally, it is not possible within one section of the present/proposed table to alternate text fields and image fields. You will need to repeat the scope section entirely.

**Present and proposed section – address details**

The section now allows the usage of OMS entry.
Depending on the role of the company of which the address needs to be included, it may happen that OMS cannot provide details. It is assumed that in those cases – more likely in the present part of that section – the details need to be completed manually. Although due to the early stage of productive OMS usage not every address might be available, it is highly recommended to use OMS for any new address to be inserted in the proposed section.

4.a Type IB and Type II variations – new indications – orphan medicinal product information

This section is only displayed if variation type IB or type II has been selected. The section can be flagged out, if not applicable:

4.a Type II variations - new indications - orphan medicinal product information
(For human medicinal products only; mark this section N/A if the variation does not relate to a new indication)

☐ Select flag if not applicable; section will not be displayed.

Has orphan designation been applied for, for this new indication?

- Yes
- No

Orphan designation procedure number: 

- Pending
- Orphan Designation Granted
- Orphan Designation Refused
- Orphan Designation Withdrawn

Information relating to orphan market exclusivity

Has any medicinal product been designated as an Orphan medicinal product for a condition relating to the new indication proposed in this variation application?

- Yes
- No

Please specify the EU Orphan Designation Number(s):

Has any of the designated Orphan medicinal product(s) been granted a marketing authorisation in the EU?

- Yes
- No
4.b Type IB and Type II variations – Paediatric Requirements

This section is only displayed if variation type IB or type II has been selected. This section can be flagged out, if not applicable.

4.b Type II variations – Paediatric requirements
(For human medicinal products only; section to be completed only for variations concerning a new indication or for variations related to PIP implementation)
(Note: The notion of ‘global marketing authorisation’ as stated in Article 6(1)2nd subparagraph of Directive 2001/83/EC, as amended, should be taken into account for products belonging to the same marketing authorisation holder)

Select flag if not applicable; section will not be displayed.

- Article 8 of Paediatric Regulation applies to this variation application since.

- This application relates to a new indication for an authorised medicinal product which:
  - is protected by a supplementary protection certificate under Regulation (EC) No 469/2008.
  - is protected by a patent which qualifies for the granting of the supplementary protection certificate.

- This application relates to a previous/ongoing/parallel procedure which triggered Article 8 requirement.

- Article 8 of the paediatric regulation does not apply to this application, since.

- This application relates to a new indication for a paediatric use marketing authorisation (PUMA).

☒ This application relates to paediatric studies submitted according to Article 45 or 46 of the paediatric regulation

☐ This application relates to paediatric studies included in a paediatric investigation plan

This application includes:

- PIP Decision Number\(^\text{15}\)

- Product-Specific Waiver Decision Number\(^\text{16}\)

- Class Waiver Decision Number

(Note: a copy of the PIP/Product-Specific Waiver decision including the paediatric Committee (PDCO) opinion and the Summary Report, is to be included in Module 1.10)

Has this application been subject to PIP compliance verification?

☐ Yes □ No

Please specify

The compliance document reference

(Note: if available, a copy of the PDCO compliance report with, where applicable, the PDCO opinion or the document issued by the national competent authority is to be included in Module 1.10)

☒ Please provide the overview table of PIP results in Module 1.10
4.c Type II variations – Extended data exclusivity/market protection

This section is only displayed if variation type II has been selected. The section can be flagged out, if not applicable

4.c Type II variations – Extended data exclusivity/market protection:

☐ Select flag if not applicable; section will not be displayed.

Consideration of this application is also requested under the following article in directive 2001/83/EC or regulation (EC) No 726/2004:


☐ Article 10(5) of Directive 2001/83/EC (one year of data exclusivity for a new indication)

☐ Article 74(a) of Directive 2001/83/EC (one year of data exclusivity for a change in classification)

(Note: The report justifying the claim for extended data exclusivity/market protection is to be provided in Module 15.3)
Annexed documents (where appropriate)

**ANNEXED DOCUMENTS (WHERE APPROPRIATE)**

The following amended product information proposals are provided in the relevant sections of the EU-CTD format or NTA volume 6B format, where applicable:

- ✔ Summary of product characteristics
- Manufacturing Authorisation Holder responsible for batch release and conditions of the Marketing Authorisation
- Labelling
- ✔ Package leaflet
- Mock-ups
- Specimen

Declaration of the applicant

Signature

Complete these sections in the same way as previous forms.
RENEWAL FROM

1. Application form for renewal of a marketing authorisation

This form is applicable to both domains and you have to make a selection at first (indicated with arrows in the figure below):

A renewal form must be provided for each form and strength of a medicinal product (except for Centrally Authorised products where renewal always covers the whole product with all its forms and strengths). Nevertheless, the product name per member state may differ. In case of combined packages and different composition of pharmaceutical products need to be addressed, several options to copy data fields are provided.

Another difference to the previous form is the indication whether the product is marketed or not (squared box), but all other details need to be completed as known from the MAA form or the variation form.

Again you have the option to populate the product details in section Qualitative and quantitative composition (section 3.)

Provide further product characteristics:
When selecting “Veterinary” this section is adapted to add the target species and it is likely the ATC vet code and respective group are chosen (although not explicitly mentioned):

The name and address of the Marketing Authorisation Holder will be handled in the same way as in other forms.
Again buttons are added to allow replication of data:

2. Approved manufacturers
Details of the role of the manufacturer can be described in the free text field on top.

## 2. APPROVED MANUFACTURERS

Authorized manufacturer(s) (or importer) responsible for **batch release** in the EEA (in accordance with Articles 4(1) and 51 of Directive 2001/83/EC, as amended, or Articles 44 and 55 of Directive 2001/82/EC (as shown in the package leaflet and where applicable in the labelling or Annex II of the Decision)

<table>
<thead>
<tr>
<th>Company Role:</th>
<th>Batch release</th>
</tr>
</thead>
<tbody>
<tr>
<td>Do you have a separate admin and manufacturer address?</td>
<td>Yes</td>
</tr>
</tbody>
</table>

Please select organisation from SPOR OMS to autofill address details. If the organisation is not found or the address details are not correct, please visit the OMS page in the SPOR portal for more information: [http://spor.ema.europa.eu/omsww/#/](http://spor.ema.europa.eu/omsww/#/)

### BfArM-Pharma

<table>
<thead>
<tr>
<th>Company name</th>
<th>BfArM-Pharma</th>
</tr>
</thead>
<tbody>
<tr>
<td>Admin Office Address</td>
<td>Kurt-Georg-Kiesinger Allee 3</td>
</tr>
<tr>
<td>City/Locality/Town/Village</td>
<td>Bonn</td>
</tr>
<tr>
<td>Admin Office State</td>
<td></td>
</tr>
<tr>
<td>Admin Office Country</td>
<td></td>
</tr>
<tr>
<td>Postcode</td>
<td>53121</td>
</tr>
<tr>
<td>Admin Office Country</td>
<td>Germany</td>
</tr>
<tr>
<td>Admin Office Telephone</td>
<td>0049 228 99 307 9999</td>
</tr>
<tr>
<td>Admin Office E-mail</td>
<td><a href="mailto:Bill.miller@bfarm.de">Bill.miller@bfarm.de</a></td>
</tr>
</tbody>
</table>

Please select organisation from SPOR OMS to autofill address details. If the organisation is not found or the address details are not correct, please visit the OMS page in the SPOR portal for more information: [http://spor.ema.europa.eu/omsww/#/](http://spor.ema.europa.eu/omsww/#/)

### BfArM-Pharma Testing Site

<table>
<thead>
<tr>
<th>Company name</th>
<th>BfArM-Pharma Testing Site</th>
</tr>
</thead>
<tbody>
<tr>
<td>Manufacturing Facility Address</td>
<td>Hans-Mueller-Platz 1</td>
</tr>
<tr>
<td>City/Locality/Town/Village</td>
<td>Bonn</td>
</tr>
<tr>
<td>Manufacturing Facility State</td>
<td></td>
</tr>
<tr>
<td>Manufacturing Facility County</td>
<td></td>
</tr>
<tr>
<td>Postcode</td>
<td>53121</td>
</tr>
<tr>
<td>Manufacturing Facility Country</td>
<td>Germany</td>
</tr>
<tr>
<td>Manufacturing Facility Telephone</td>
<td>0049 228 99 307 8888</td>
</tr>
<tr>
<td>Manufacturer Facility E-mail</td>
<td><a href="mailto:bdb.scholz@bfarm.de">bdb.scholz@bfarm.de</a></td>
</tr>
</tbody>
</table>
The free text field can be used to indicate the 'role' of the manufacturer for applications with multiple active substances, excipients and manufacturers. For example, this field can be used to indicate the manufacturer of the 'Drug product' and manufacturer of the 'solvent' or the batch release of the product. Leave this field blank if not required.

For blood products and vaccines:
State laboratory or laboratory designated for official batch release, as accordance with Articles 111(1), 113, 114 (1)-(2) and 115 of Directive 2001/83/EC as amended.

- Laboratory Name
- Do you have admin address and manufacturer address? Yes No
- Company name
- Admin Office Address 1
- Admin Office Address 2
- Postcode
- Admin Office Country
- Admin Office Telephone
- Admin Office Telefax
- Admin Office E-mail

For the site(s) in EEA or in countries where an MRA or other EU arrangements apply, where batch control/testing takes place, as required by Article 51 of Directive 2001/83/EC as amended or Article 55 of Directive 2001/82/EC, if different from above.

- Site(s) in EEA or in countries where an MRA or other EU arrangements apply, where batch control/testing takes place, as required by Article 51 of Directive 2001/83/EC as amended or Article 55 of Directive 2001/82/EC, if different from above.

- Do you have a separate admin and manufacturer address? Yes No
- Company name
- Manufacturing Facility Address 1
- Manufacturing Facility Address 2
- Postcode
- Manufacturing Facility Country
- Manufacturing Facility Telephone
- Manufacturing Facility Telefax
- Manufacturing Facility E-mail

In the various address fields you will find buttons to copy the address details as appropriate.
3. Quantitative and qualitative composition in terms of the active substance(s) and the excipient(s)

This section is concluded with a tabular listing of changes of the product information texts. This table can be provided as a separate document attached to the application form as well.

Per section or subsection of the SmPC or PL you should use a separate line item by item to be changed.
If you formatted text is to be used follow the tips provided [here](#).

### 4. Documents appended to this application

In cases where a renewal is being made for either a human or veterinary medicinal product following the nationally authorised procedure (National authorisation in MRP/DCP or National authorisation only), users can elect to have a shortened renewal procedure and provide the appropriate justification as displayed below:

<table>
<thead>
<tr>
<th>DOCUMENTS APPENDED TO THIS APPLICATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Product subject to shortened renewal</td>
</tr>
<tr>
<td>Shortened Procedure Reason</td>
</tr>
</tbody>
</table>

For the remaining Module 1 section, depending on your selections, complete the list of documents you will attach.
Module 1

1.0 Cover letter

1.1 Comprehensive table of content (not applicable for centrally authorised medicinal products)

1.2 Renewal Application Form with the following annexes:

A list of all authorised product presentations for which renewal is sought in tabular format

Details on contact persons:

- Qualified person in the EEA for Pharmacovigilance
- Contact person in the EEA with overall responsibility for product defects and recalls
- Contact person for scientific service in the EEA in charge of information about the medicinal product

Chronological list of all post-authorization submissions since grant of the Marketing authorisation or last renewal: a list of all approved or pending Type IA/IB and Type II variations, Extensions, Art 61(3) Notifications, USR and PSUR, giving the procedure number (where applicable), date of submission, date of approval (if approved) and brief description of the change.

Chronological list of conditions and Specific Obligations (for centrally authorised products) submitted since grant of marketing authorisation or last renewal indicating scope, status, date of submission and date when issue has been resolved (where applicable)

Revised list of all remaining conditions and any Specific Obligations (for centrally authorised products) (where applicable)

A statement, or when available, a certificate of GMP compliance, not more than three years old, for the manufacturer(s) of the medicinal product listed in the application issued by an EEA competent authority or MRA partner authority. A reference to the EudraGMP database will suffice, once this is available

For manufacturing sites of the medicinal product not located in the EEA or in the territory of an MRA partner, a list of the most recent GMP inspections carried out by other authorities indicating the date, inspection team and outcome

A declaration by the Qualified Person (QP) of each of the manufacturing authorisation holders (i.e. located in the EEA) listed in the application form where the active substance(s) is used as a starting material, that the active substance(s) is manufactured in accordance with the guidelines on good manufacturing practice for starting materials as adopted by the EU

Declaration and Signature

Complete this section in the same way as previous forms.
DECLARATION AND SIGNATURE

I hereby make application for the above Marketing Authorisation to be renewed. I declare that the quality of the product, in respect of the methods of preparation and control, has been regularly updated by variation procedure to take account of technical and scientific progress in accordance with Article 23 of Directive 2001/83/EC or Article 27 (1) of Directive 2001/82/EC or Article 16 or Article 41(1) of Regulation (EC) No 726/2004. The product conforms with current CHMP/CVMP quality guidelines where relevant. I confirm that no changes have been made to the product particulars other than those approved by the Competent Authority.

☑ Proof of payment (when relevant)

Have all relevant fees been prepaid to competent authorities?
☑ Yes (for fees paid, attach proof of payment in Annex)
☐ No

For Member State(s)

Please specify fee category under National rules

Title
First name
Surname
Status (Job Title)
Date
Signatory

Additional Signatory